Ashley V. DiMarco

Ashley V. DiMarco

Auto-generated profile, based on publicly available information

Ashley V. DiMarco

Department of Translational Oncology, Genentech, Inc., South San Francisco, California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Cancer Research Communications
Verified
Journal Article
Open access
NGNina Marie G. Garcia
Nina Marie G. Garcia
JBJessica N. Becerra
Jessica N. Becerra
SSSharan Srinivasan
Sharan Srinivasan
BMBrock J. McKinney
Brock J. McKinney
ADAshley V. DiMarco
Ashley V. DiMarco
JAJames V. Alvarez
James V. Alvarez
APOBEC mutagenesis is one of the most common endogenous sources of mutations in human cancer and is a major source of genetic intratumor heterogeneity. High levels of APOBEC mutagenesis are associated with poor prognosis and aggressive disease across diverse cancers, but the mechanistic and functional impacts of APOBEC mutagenesis on tumor evolution and therapy resistance remain relatively unexplored. To address this, we investigated the contribution of APOBEC mutagenesis to acquired therapy resistance in a model of EGFR-mutant non–small cell lung cancer. We find that inhibition of EGFR in lung cancer cells leads to a rapid and pronounced induction of APOBEC3 expression and activity. Functionally, APOBEC expression promotes the survival of drug-tolerant persister cells (DTP) following EGFR inhibition. Constitutive expression of APOBEC3B alters the evolutionary trajectory of acquired resistance to the EGFR inhibitor gefitinib, making it more likely that resistance arises through de novo acquisition of the T790M gatekeeper mutation and squamous transdifferentiation during the DTP state. APOBEC3B expression is associated with increased expression of the squamous cell transcription factor ΔNp63 and squamous cell transdifferentiation in gefitinib-resistant cells. Knockout of p63 in gefitinib-resistant cells reduces the expression of the ΔNp63 target genes IL-1α/β and sensitizes these cells to the third-generation EGFR inhibitor osimertinib. These results suggest that APOBEC activity promotes acquired resistance by facilitating evolution and transdifferentiation in DTPs and that approaches to target ΔNp63 in gefitinib-resistant lung cancers may have therapeutic benefit. Significance: APOBEC mutagenesis is a common source of genetic heterogeneity in cancer, and APOBEC mutational signatures are enriched in metastatic and drug-resistant tumors. However, the mechanisms through which APOBEC3 enzymes promote tumor evolution remain unknown. In this study, we show that APOBEC3 activity contributes to the development of therapy-resistant cancer cells by promoting evolution of DTP cells. These findings offer insights into the role of APOBEC mutagenesis in cancer progression.

3 July 2025 in Cancer Research
Verified
Journal Article
Closed access
ADAshley V. DiMarco
Ashley V. DiMarco
MRMirunalini Ravichandran
Mirunalini Ravichandran
JLJeff Lau
Jeff Lau
ALAnthony Lima
Anthony Lima
JLJennifer Lacap
Jennifer Lacap
DMDanilo Maddalo
Danilo Maddalo
RIT1 is a RAS-family guanosine triphosphatase that is mutated in 2.4% and amplified in up to 14% of patients with lung adenocarcinoma. Yet the oncogenic potential of RIT1 in the lungs has not been fully established. Consequently, patients with RIT1 alterations are considered “oncogene-negative” and are not eligible for any targeted therapy in the clinic. The role of RIT1 in cancer has been historically understudied due to the lack of in vitro and in vivo models harboring RIT1 alterations. In this study, we generated a murine model of RIT1M90I-mutant lung cancer. RIT1M90I expression induced tumorigenesis in the lungs, and the tumors displayed histopathologic features similar to lung adenocarcinoma in humans. An unbiased chemical compound screen leveraging this model revealed a sensitivity to inhibitors of the MAPK, PI3K, and cholesterol biosynthesis pathways in RIT1-mutant cell lines. The SHP2 inhibitor, migoprotafib, in combination with other MAPK pathway–targeted therapies, effectively suppressed the growth of RIT1-mutant cells ex vivo and in vivo. Finally, RIT1M90I drove resistance to the KRASG12C inhibitor, divarasib, and the combination with migoprotafib reverted this phenotype. Together, these data show that RIT1M90I is a bona fide oncogenic driver of lung cancer and a mediator of targeted therapy resistance as a co-occurring mutation and suggest that patients with RIT1-altered cancer may benefit from combination treatments with an SHP2 inhibitor. Significance: Development of a mouse model of RIT1M90I-altered non-small cell lung cancer reveals that RIT1M90I is a driver of lung tumorigenesis and that RIT1-mutated tumors are sensitive to MAPK pathway inhibitors. See related commentary by Wu and Vaishnavi, p. 3186 See related article by Mozzarelli et al., p. 3196

2 September 2025
Verified
Other
Open access
ADAshley V. DiMarco
Ashley V. DiMarco
MRMirunalini Ravichandran
Mirunalini Ravichandran
JLJeff Lau
Jeff Lau
ALAnthony Lima
Anthony Lima
JLJennifer Lacap
Jennifer Lacap
DMDanilo Maddalo
Danilo Maddalo
RIT1 is a RAS-family guanosine triphosphatase that is mutated in 2.4% and amplified in up to 14% of patients with lung adenocarcinoma. Yet the oncogenic potential of RIT1 in the lungs has not been fully established. Consequently, patients with RIT1 alterations are considered “oncogene-negative” and are not eligible for any targeted therapy in the clinic. The role of RIT1 in cancer has been historically understudied due to the lack of in vitro and in vivo models harboring RIT1 alterations. In this study, we generated a murine model of RIT1M90I-mutant lung cancer. RIT1M90I expression induced tumorigenesis in the lungs, and the tumors displayed histopathologic features similar to lung adenocarcinoma in humans. An unbiased chemical compound screen leveraging this model revealed a sensitivity to inhibitors of the MAPK, PI3K, and cholesterol biosynthesis pathways in RIT1-mutant cell lines. The SHP2 inhibitor, migoprotafib, in combination with other MAPK pathway–targeted therapies, effectively suppressed the growth of RIT1-mutant cells ex vivo and in vivo. Finally, RIT1M90I drove resistance to the KRASG12C inhibitor, divarasib, and the combination with migoprotafib reverted this phenotype. Together, these data show that RIT1M90I is a bona fide oncogenic driver of lung cancer and a mediator of targeted therapy resistance as a co-occurring mutation and suggest that patients with RIT1-altered cancer may benefit from combination treatments with an SHP2 inhibitor.Significance:Development of a mouse model of RIT1M90I-altered non-small cell lung cancer reveals that RIT1M90I is a driver of lung tumorigenesis and that RIT1-mutated tumors are sensitive to MAPK pathway inhibitors.See related commentary by Wu and Vaishnavi, p. 3186See related article by Mozzarelli et al., p. 3196

2 September 2025
Verified
Other
Open access
PDF file
ADAshley V. DiMarco
Ashley V. DiMarco
MRMirunalini Ravichandran
Mirunalini Ravichandran
JLJeff Lau
Jeff Lau
ALAnthony Lima
Anthony Lima
JLJennifer Lacap
Jennifer Lacap
DMDanilo Maddalo
Danilo Maddalo
Supplementary Figure S2: Ex vivo RIT1 cell lines have Trp53 genetic knockout and therapeutic vulnerabilities include MAPK/PI3K inhibitors and statins.

2 September 2025
Verified
Other
Open access
PDF file
ADAshley V. DiMarco
Ashley V. DiMarco
MRMirunalini Ravichandran
Mirunalini Ravichandran
JLJeff Lau
Jeff Lau
ALAnthony Lima
Anthony Lima
JLJennifer Lacap
Jennifer Lacap
DMDanilo Maddalo
Danilo Maddalo
Supplementary Figure S4: (A) NCI-H358-RIT1M90I cells are resistant to divarasib single agent treatment and can be re-sensitized with divarasib and migoprotafib combination both in vitro and in vivo.

2 September 2025
Verified
Other
Open access
ADAshley V. DiMarco
Ashley V. DiMarco
MRMirunalini Ravichandran
Mirunalini Ravichandran
JLJeff Lau
Jeff Lau
ALAnthony Lima
Anthony Lima
JLJennifer Lacap
Jennifer Lacap
DMDanilo Maddalo
Danilo Maddalo
Supplementary Table S1: Assessment of immunohistochemistry staining intensity on lungs from RIT1 mice. Pathological findings are summarized for all tumors within each animal. Localization of CD3-positive T cells is described. IHC staining intensity is qualitatively scored as +++; strongly positive, +/-; mixed and description is included, -; negative.